Ratings by William Blair (Andy T. Hsieh)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 8/12/2026 | Cardiff Oncology | CRDF | Downgrade | Market Perform (Outperform) |
1.03 (1.03) |
0% | Details | |
| 8/3/2026 | Lantheus Holdings | LNTH | Downgrade | Market Perform (Outperform) |
99.64 (100.88) |
1.24% | Details | |
| 5/12/2026 | Kailera Therapeutics | KLRA | New Coverage | Outperform (N/A) |
22.93 (16.41) |
-28.43% | Details | |
| 3/26/2026 | Cardiff Oncology | CRDF | Maintain | Outperform (N/A) |
|
Details | ||
| 3/23/2026 | Pyxis Oncology Inc. | PYXS | Maintain | Market Perform (N/A) |
|
Details | ||
| 3/17/2026 | Lantheus Holdings | LNTH | Maintain | Outperform (N/A) |
|
Details | ||
| 2/26/2026 | Lantheus Holdings | LNTH | Upgrade | Outperform (Market Perform) |
75.72 (99.64) |
31.59% | Details | |
| 6/9/2025 | Elevation Oncology | ELEV | Downgrade | Market Perform (Outperform) |
0.32 (0.37) |
15.63% | Details | |
| 1/3/2025 | Elevation Oncology | ELEV | New Coverage | Outperform (N/A) |
0.60 (0.37) |
-38.33% | Details | |
| 2/12/2024 | CymaBay Therapeutic | CBAY | Downgrade | Market Perform (Outperform) |
25.69 (32.48) |
26.43% | Details | |
| 12/18/2023 | Lantheus Holdings | LNTH | Downgrade | Market Perform (Outperform) |
76.04 (75.72) |
-0.42% | Details | |
| 9/29/2023 | Lantheus Holdings | LNTH | New Coverage | Outperform (N/A) |
69.53 (100.88) |
45.09% | Details | |
| 4/5/2023 | CymaBay Therapeutic | CBAY | New Coverage | Outperform (N/A) |
8.61 (32.48) |
277.24% | Details | |
| 1/5/2022 | Cardiff Oncology | CRDF | New Coverage | Outperform (N/A) |
6.29 (1.03) |
-83.62% | Details | |
| 12/1/2021 | BeyondSpring Inc. | BYSI | Downgrade | Market Perform (Outperform) |
14.23 (0.60) |
-95.78% | Details | |
| 5/25/2021 | Vaccitech | VACC | New Coverage | Outperform (N/A) |
14.58 (5.00) |
-65.71% | Details |
